Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S.K. Mok, Yi-Long Lung Cancer Wu, Iveta Kudaba et al. · The Lancet · 2019
Cited by 3,303 works. doi:10.1016/s0140-6736(18)32409-7
Authors
- Tony S.K. Mok
- Yi-Long Lung Cancer Wu
- Iveta Kudaba
- Dariusz Mirosław Kowalski
- Byoung Chul Cho
- H.Z. Turna
- Gilberto de Castro
- Vichien Srimuninnimit
- Константин Константинович Лактионов
- Igor Bondarenko
- Kaoru Kubota
- Gregory M. Lubiniecki
- Jin Zhang
- Debra A. Kush
- Gilberto De Lima Lopes Jr.
- Grigory Adamchuk
- Myung‐Ju Ahn
- Aurelia Alexandru
- Özden Altundağ
- Anna V. Alyasova
References
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma